- Article metrics
- Last updated: Wed, 2 Jul 2025 7:19:42 Z
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Access & Citations
-
- 129k
- Article Accesses
-
- 320
- Citations
Citation counts are provided by Dimensions and depend on their data availability. Counts will update daily, once available.
Online attention
- 570 tweeters
- 4 blogs
- 3 Facebook pages
- 189 news outlets
- 2 Redditors
- 1 Video uploaders
- 307 Mendeley
This article is in the 99th percentile (ranked 273rd) of the 442,489 tracked articles of a similar age in all journals and the 97th percentile (ranked 23rd) of the 1,067 tracked articles of a similar age in Nature
View more on Altmetric
Altmetric calculates a score based on the online attention an article receives. Each coloured thread in the circle represents a different type of online attention. The number in the centre is the Altmetric score. Social media and mainstream news media are the main sources that calculate the score. Reference managers such as Mendeley are also tracked but do not contribute to the score. Older articles often score higher because they have had more time to get noticed. To account for this, Altmetric has included the context data for other articles of a similar age.
Mentions in news and blogs
-
An anti-cancer drug could potentially cure acute myeloid leukemia
Interesting Engineering -
Un fármaco experimental logra remitir la leucemia aguda en 18 pacientes
López-Dóriga Digital -
Revumenib Shows Promise in Treating Advanced Acute Myeloid Leukemia
Cancer Currents: An NCI Cancer Research Blog -
​Oral Inhibitor Revumenib for Treating Genetic Subtypes of Acute Leukemia
Online First/Online Only: Posts
This list highlights individual mainstream news articles and blogs that cite the article. Not all news and blogs link to articles in a way that Altmetric can pick up, so they are not representative of all media. Altmetric are responsible for the curation of this list and provide updates hourly.